Doreen Ho, MD

Dr. Doreen Ho serves as Clinical Director and Physician Investigator at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. Her clinical and research efforts focus on Amyotrophic Lateral Sclerosis (ALS) and the management of complex motor neuron diseases, including Spinal Muscular Atrophy (SMA). She is driven by a mission-oriented approach that integrates innovative clinical research with a strong commitment to the comprehensive well-being of patients and their families.

Education

• Dr. Ho earned her medical degree from Tufts University School of Medicine and completed her specialized training in neurology and neuromuscular medicine within the Harvard medical system.

Published Works

• Beyond her work in ALS, she has published extensively on neuromuscular diagnostics, including high-resolution ultrasound and the management of peripheral neuropathies.

Professional Accomplishments

• HEALEY ALS Platform Trial: She plays a pivotal role in the first platform trial in ALS, an innovative study design that tests multiple investigational treatments simultaneously to find effective therapies faster.
• Clinical Innovation: Her research in ALS focuses on enhancing clinical trial operations, expanding access to care, and developing pathways for emerging therapeutics in ALS and SMA. She leads the clinical team at the Sean M. Healey & AMG Center for ALS, one of the highest volume multidisciplinary clinics in the world. She established one of the first and largest Adult SMA Clinics in the country, in response to the evolving landscape of SMA care in the era of gene-targeted and disease-modifying therapies, addressing a critical need for coordinated, interdisciplinary care.
• Holistic Care Advocacy: Dr. Ho is a vocal advocate for addressing the holistic aspects of ALS and motor neuron diseases. Her clinical philosophy centers on the partnership between the care team and the patient, emphasizing shared decision-making and individualized symptomatic treatment.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.